Related Experiment Video

Updated: Nov 30, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K

Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis

Weimin Li1, Qingqin Ma2, Quan Liu3

  • 1Central Neurosurgery Group of Encephalopath, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, 130021, Changchun, Jilin, China.

Journal of Molecular Neuroscience : MN
|November 14, 2020
PubMed

Insights

This study reveals that circ-VPS18 promotes temozolomide (TMZ) resistance in glioma by sponging miR-370, which targets RUNX1. Reducing circ-VPS18 enhances TMZ sensitivity and inhibits glioma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioma is a common brain tumor often treated with temozolomide (TMZ).
  • Acquired resistance to TMZ significantly complicates glioma treatment and necessitates understanding underlying mechanisms.
  • Circular RNAs (circRNAs) are emerging as critical regulators in various cancers, including glioma.

Purpose of the Study:

  • To investigate the role of circ-VPS18 in temozolomide (TMZ) resistance in glioma.
  • To elucidate the molecular mechanism by which circ-VPS18 influences TMZ sensitivity and glioma progression.
  • To explore the potential of targeting the circ-VPS18/miR-370/RUNX1 axis for overcoming TMZ resistance.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot were used to detect expression levels of circ-VPS18, miR-370, RUNX1, MRP1, and MDR1.
  • Cell counting kit-8 (CCK-8), flow cytometry, and transwell assays assessed the functional effects of circ-VPS18 knockdown on TMZ sensitivity and glioma cell behaviors.
  • Dual-luciferase reporter assays and in vivo tumor formation assays were employed to validate molecular interactions and therapeutic efficacy.

Main Results:

  • Circ-VPS18 and RUNX1 expression were upregulated, while miR-370 was downregulated in glioma cells and tissues, particularly in TMZ-resistant samples.
  • Knockdown of circ-VPS18 significantly enhanced TMZ sensitivity, induced apoptosis, and suppressed viability, migration, and invasion of glioma cells.
  • Circ-VPS18 acts as a molecular sponge for miR-370, and miR-370 targets RUNX1, establishing a regulatory axis that impacts TMZ resistance and glioma progression.

Conclusions:

  • Circ-VPS18 promotes TMZ resistance in glioma by sponging miR-370, leading to increased RUNX1 expression.
  • Targeting circ-VPS18 offers a potential therapeutic strategy to overcome temozolomide resistance in glioma.
  • The circ-VPS18/miR-370/RUNX1 pathway provides novel insights into glioma treatment resistance.
Keywords:
Circ-VPS18GliomaMiR-370RUNX1SensitivityTMZ

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.9K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.8K

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
955
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K